JP2020516617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516617A5 JP2020516617A5 JP2019554986A JP2019554986A JP2020516617A5 JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5 JP 2019554986 A JP2019554986 A JP 2019554986A JP 2019554986 A JP2019554986 A JP 2019554986A JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5
- Authority
- JP
- Japan
- Prior art keywords
- pgdh inhibitor
- substituted
- pgdh
- aryl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heteroaryl aryl Chemical group 0.000 claims 18
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims 15
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 235000021317 phosphate Nutrition 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000005277 alkyl imino group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 2
- 125000004467 aryl imino group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 231100000457 cardiotoxic Toxicity 0.000 claims 2
- 230000001451 cardiotoxic effect Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
- 229960004176 aclarubicin Drugs 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 229960000641 zorubicin Drugs 0.000 claims 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022119729A JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483177P | 2017-04-07 | 2017-04-07 | |
| US62/483,177 | 2017-04-07 | ||
| PCT/US2018/026739 WO2018187810A1 (en) | 2017-04-07 | 2018-04-09 | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Division JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516617A JP2020516617A (ja) | 2020-06-11 |
| JP2020516617A5 true JP2020516617A5 (https=) | 2020-07-30 |
| JP7178360B2 JP7178360B2 (ja) | 2022-11-25 |
Family
ID=63712743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554986A Active JP7178360B2 (ja) | 2017-04-07 | 2018-04-09 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11426420B2 (https=) |
| EP (1) | EP3606520A4 (https=) |
| JP (2) | JP7178360B2 (https=) |
| CN (1) | CN110891568A (https=) |
| AU (1) | AU2018249956B2 (https=) |
| CA (1) | CA3059255A1 (https=) |
| WO (1) | WO2018187810A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN118059093A (zh) | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| CA3059255A1 (en) | 2017-04-07 | 2018-10-11 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
| CA3168494A1 (en) | 2020-01-23 | 2021-07-29 | Roopa Rai | Pgdh inhibitors and methods of making and using |
| CR20220654A (es) | 2020-05-20 | 2023-08-24 | Rodeo Therapeutics Corp | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta |
| US20230210829A1 (en) * | 2020-06-11 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Rejuvenation of aged tissues by inhibition of the pge2 degrading enzyme, 15-pgdh |
| CA3190602A1 (en) * | 2020-08-07 | 2022-02-10 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration |
| WO2025170936A1 (en) * | 2024-02-05 | 2025-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and methods for treating cardiac dysfunction |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR80916B (en) | 1983-11-14 | 1985-03-12 | Dow Chemical Co | Method of preparing 1,2,4-triazolo (1,5-a)-pyrimidine-2-sulfonyl chlorides |
| DE59008552D1 (de) | 1989-01-11 | 1995-04-06 | Ciba Geigy Ag | Antidots zur Verbesserung der Kulturpflanzenvertäglichkeit agrochemischer Wirkstoffe. |
| EP0434624B1 (de) | 1989-12-22 | 1995-02-08 | Ciba-Geigy Ag | Triazolylsulfonamide |
| SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| ATE266397T1 (de) | 1997-02-04 | 2004-05-15 | Murray A Johnstone | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
| US20030096823A1 (en) | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法 |
| US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| EA009920B1 (ru) | 2003-08-29 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения пиримидотиофена |
| JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するためのチエノピリジン |
| WO2006078676A2 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| BRPI0620205A2 (pt) | 2005-12-20 | 2011-11-01 | Richter Gedeon Nyrt | novos compostos |
| WO2009073460A2 (en) | 2007-12-03 | 2009-06-11 | Bausch & Lomb Incorporated | Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US9216983B2 (en) | 2007-12-21 | 2015-12-22 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| US8637558B2 (en) * | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
| JP5818266B2 (ja) | 2009-09-29 | 2015-11-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | ジヒドロオロット酸デヒドロゲナーゼの阻害剤である抗マラリア剤 |
| GB201107197D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Compounds |
| EP2758544B1 (en) | 2011-09-23 | 2017-10-18 | Academisch Medisch Centrum | Materials and methods for prognosis of progression of barrett's esophagus |
| WO2013112699A2 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| DK2838533T3 (da) * | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CA2966577C (en) | 2013-11-19 | 2023-09-26 | Zhongren ZHOU | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma |
| US10144742B2 (en) | 2014-04-18 | 2018-12-04 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
| EP3179995B1 (en) | 2014-08-12 | 2018-11-07 | University of Pécs (Pécsi Tudományegyetem) | Methods and materials for reducing ischemia-reperfusion injury |
| CN118059093A (zh) | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| JP2018511616A (ja) | 2015-04-14 | 2018-04-26 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物および方法 |
| EP3423067B1 (en) * | 2016-03-04 | 2025-07-23 | The Board of Trustees of the Leland Stanford Junior University | Inhibitors of 15-hydroxyprostaglandin dehydrogenase for muscle regeneration |
| CA3031091A1 (en) | 2016-07-18 | 2018-01-25 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CA3059255A1 (en) | 2017-04-07 | 2018-10-11 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
| WO2018218251A1 (en) | 2017-05-26 | 2018-11-29 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN120463721A (zh) * | 2018-11-21 | 2025-08-12 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| JP2021134242A (ja) | 2020-02-25 | 2021-09-13 | 株式会社アイティー技研 | 鉱物油精製方法及び装置 |
| JP7574640B2 (ja) | 2020-12-23 | 2024-10-29 | 株式会社リコー | 画像処理装置、画像処理システム、方法およびプログラム |
-
2018
- 2018-04-09 CA CA3059255A patent/CA3059255A1/en active Pending
- 2018-04-09 JP JP2019554986A patent/JP7178360B2/ja active Active
- 2018-04-09 AU AU2018249956A patent/AU2018249956B2/en active Active
- 2018-04-09 US US16/603,544 patent/US11426420B2/en active Active
- 2018-04-09 CN CN201880028200.4A patent/CN110891568A/zh active Pending
- 2018-04-09 EP EP18781322.5A patent/EP3606520A4/en active Pending
- 2018-04-09 WO PCT/US2018/026739 patent/WO2018187810A1/en not_active Ceased
-
2022
- 2022-07-27 JP JP2022119729A patent/JP2022141930A/ja active Pending
- 2022-08-23 US US17/893,777 patent/US20230165883A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516617A5 (https=) | ||
| JP2024040167A5 (https=) | ||
| JP2020510054A5 (https=) | ||
| RU2016142704A (ru) | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR | |
| RU2013141829A (ru) | Цитотоксические производные бензодиазепина | |
| KR101230085B1 (ko) | ７―(２,５-디히드로―４-이미다조［１,２-ａ］피리딘-３-일-２,５-디옥소-１ｈ-피롤-３-일)-９-플루오로-１,２,３,４-테트라히드로-２-(１-피페리디닐카르보닐)-피롤로［３,２,１-ｊｋ］［１,４］벤조디아제핀에 의한 암 화학요법의 강화 | |
| JP2009515890A5 (https=) | ||
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| JP2006036796A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2010511626A5 (https=) | ||
| RU2006138040A (ru) | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ | |
| JP2018511616A5 (https=) | ||
| JP2021508697A5 (https=) | ||
| JP2011509260A5 (https=) | ||
| AU2016279051A1 (en) | Delivery systems for controlled drug release | |
| JP2018527292A5 (https=) | ||
| JPWO2019140128A5 (https=) | ||
| JP2009541225A5 (https=) | ||
| JP2009511599A5 (https=) | ||
| US11634405B2 (en) | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | |
| CA2260060C (en) | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| MX2024010782A (es) | Agentes ligadores de fenil maleimida | |
| JP2000503999A (ja) | ジスタマイシン誘導体、その調製方法、および抗腫瘍および抗ウイルス剤としてのその使用 |